F J Sánchez-Gómez1, J M González-Morena1, Y Vida2,3, E Pérez-Inestrosa2,3, M Blanca4, M J Torres4, D Pérez-Sala1. 1. Department of Chemical and Physical Biology, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain. 2. Department of Organic Chemistry, University of Málaga, IBIMA, Málaga, Spain. 3. Andalusian Center for Nanomedicine and Biotechnology-BIONAND, Parque Tecnológico de Andalucía, Málaga, Spain. 4. Allergy Unit, IBIMA-Regional University Hospital of Málaga, UMA, Málaga, Spain.
Abstract
BACKGROUND: Allergic reactions to β-lactams are among the most frequent causes of drug allergy and constitute an important clinical problem. Drug covalent binding to endogenous proteins (haptenation) is thought to be required for activation of the immune system. Nevertheless, neither the nature nor the role of the drug protein targets involved in this process is fully understood. Here, we aim to identify novel intracellular targets for haptenation by amoxicillin (AX) and their cellular fate. METHODS: We have treated B lymphocytes with either AX or a biotinylated analog (AX-B). The identification of protein targets for haptenation by AX has been approached by mass spectrometry and immunoaffinity techniques. In addition, intercellular communication mediated by the delivery of vesicles loaded with AX-B-protein adducts has been explored by microscopy techniques. RESULTS: We have observed a complex pattern of AX-haptenated proteins. Several novel targets for haptenation by AX in B lymphocytes have been identified. AX-haptenated proteins were detected in cell lysates and extracellularly, either as soluble proteins or in lymphocyte-derived extracellular vesicles. Interestingly, exosomes from AX-B-treated cells showed a positive biotin signal in electron microscopy. Moreover, they were internalized by endothelial cells, thus supporting their involvement in intercellular transfer of haptenated proteins. CONCLUSIONS: These results represent the first identification of AX-mediated haptenation of intracellular proteins. Moreover, they show that exosomes can constitute a novel vehicle for haptenated proteins, and raise the hypothesis that they could provide antigens for activation of the immune system during the allergic response.
BACKGROUND: Allergic reactions to β-lactams are among the most frequent causes of drug allergy and constitute an important clinical problem. Drug covalent binding to endogenous proteins (haptenation) is thought to be required for activation of the immune system. Nevertheless, neither the nature nor the role of the drug protein targets involved in this process is fully understood. Here, we aim to identify novel intracellular targets for haptenation by amoxicillin (AX) and their cellular fate. METHODS: We have treated B lymphocytes with either AX or a biotinylated analog (AX-B). The identification of protein targets for haptenation by AX has been approached by mass spectrometry and immunoaffinity techniques. In addition, intercellular communication mediated by the delivery of vesicles loaded with AX-B-protein adducts has been explored by microscopy techniques. RESULTS: We have observed a complex pattern of AX-haptenated proteins. Several novel targets for haptenation by AX in B lymphocytes have been identified. AX-haptenated proteins were detected in cell lysates and extracellularly, either as soluble proteins or in lymphocyte-derived extracellular vesicles. Interestingly, exosomes from AX-B-treated cells showed a positive biotin signal in electron microscopy. Moreover, they were internalized by endothelial cells, thus supporting their involvement in intercellular transfer of haptenated proteins. CONCLUSIONS: These results represent the first identification of AX-mediated haptenation of intracellular proteins. Moreover, they show that exosomes can constitute a novel vehicle for haptenated proteins, and raise the hypothesis that they could provide antigens for activation of the immune system during the allergic response.
Authors: Monday O Ogese; Rosalind E Jenkins; Kareena Adair; Arun Tailor; Xiaoli Meng; Lee Faulkner; Bright O Enyindah; Amy Schofield; Rafael Diaz-Nieto; Lorenzo Ressel; Gina L Eagle; Neil R Kitteringham; Chris E Goldring; B Kevin Park; Dean J Naisbitt; Catherine Betts Journal: Hepatology Date: 2019-06-29 Impact factor: 17.425
Authors: María A Pajares; Tahl Zimmerman; Francisco J Sánchez-Gómez; Adriana Ariza; María J Torres; Miguel Blanca; F Javier Cañada; María I Montañez; Dolores Pérez-Sala Journal: Front Pharmacol Date: 2020-03-04 Impact factor: 5.810
Authors: Ángela Martín-Serrano; Juan M Gonzalez-Morena; Nekane Barbero; Adriana Ariza; Francisco J Sánchez Gómez; Ezequiel Pérez-Inestrosa; Dolores Pérez-Sala; Maria J Torres; María I Montañez Journal: Front Pharmacol Date: 2020-11-18 Impact factor: 5.810
Authors: Juan M González-Morena; Francisco J Sánchez-Gómez; Yolanda Vida; Ezequiel Pérez-Inestrosa; María Salas; María I Montañez; Alessandra Altomare; Giancarlo Aldini; María A Pajares; Dolores Pérez-Sala Journal: Front Pharmacol Date: 2022-01-13 Impact factor: 5.810